Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
10. Januar 2022 06:30 ET
|
Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...